Shows varying durability of anti-CD38 antibody responses in immune thrombocytopenia, suggesting broader immune modulation implications.
Anti-CD38 monoclonal antibodies have demonstrated rapid responses in immune thrombocytopenia, with response rates across several agents ranging from moderate to high. However, the durability of these responses after treatment discontinuation appears to vary. The therapeutic effects of anti-CD38 antibodies likely extend beyond depletion of CD38⁺ plasma cells and may involve broader modulation of the immune system.
No takes yet. Share an insight, caveat, or question.
Ghanima et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: